Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)
A. M Mohamed, M. Balsat, M. Thenoz, C. Koering, L. Payen-Gay, M. Cheok, H. Mortada, D. Auboeuf, C. Pinatel, M. El-Hamri, C. Dumontet, E. Cros, P. Flandrin-Gresta, O. Nibourel, C. Preudhomme, M. Michallet, X. Thomas, F. Nicolini, F. Solly, D. Guyotat, L. Campos, E. Wattel, and F. Mortreux
(2016)
Oncotarget, 7(3):2889–2909.